Guests from Overseas

Professor of Oncology, Alfiero Foundation Chair and Clinical Chief of Breast Surgery,
Breast Program Leader, and Breast Disease Site Service Line Leader
Department of Surgical Oncology and Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm & Carlton Streets, Buffalo, New York 14263
E-Mail: kazuaki.takabe@roswellpark.org Ph: 716-845-5128, Fax: 716-845-5705 @KazuTakabe
https://www.roswellpark.edu/kazuaki-takabe https://www.roswellpark.org/kazuaki-takabe
Professor of Surgery with Tenure, Department of Surgery
University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York
Liaison Professor, Niigata University Graduate School of Medicine and Dentistry (Japan)
Affiliate Professor, Tokyo Medical University School of Medicine (Japan)
Affiliate Professor, Yokohama City University School of Medicine (Japan)
Affiliate Professor, Fukushima Medical University (Japan)

###

Woo Kyung Moon, MD, PhD is currently the professor in the Department of Radiology at Seoul National University College of Medicine, Seoul National University Hospital and a vice president of Korean Breast Cancer Society (KBCS). In addition to his clinical and teaching work, Dr. Moon’s ongoing area of research include prospective multicenter clinical trials of non-contrast diffusion-weighted MRI for breast cancer screening, the use of background echotexture as markers of breast cancer risk, and development of imaging biomarkers using deep learning and biological techniques. He published more than 320 SCI papers including 55 publications in Radiology (RSNA) and four textbooks on breast imaging. In addition, He translated and published three Japanese books into Korean, including the JABTS Breast Ultrasound Diagnostic Guidelines. Dr. Moon served as the president of Korean Society of Breast Imaging in 2011-2014 and is the Fellow in the Korean Academy of Science and Technology (KAST) and the National Academy of Medicine of Korea (NAMOK).

現職
Professor
Chief, Breast Imaging Section
Director, Breast Imaging Research
Department of Radiology, the University of Chicago

専門分野: Breast Imaging

宮城県出身
東北大学医学部卒　（1987年）
医学博士　（1996年、東北大学）

職歴
東北大学付属病院、放射線科（1987-1990、研修医）
宮城県公立佐沼総合病院、放射線科（1990-1992、スタッフ）
国立がんセンター中央病院、放射線診断部（1992-1995、レジデント）
東北大学医学部付属病院、放射線科（1995-1996、助手）
聖路加国際病院、放射線科（1996-2000、スタッフ）
シカゴ大学生物科学部門、放射線科（2000-2003、研究員）

シカゴ大学医学部、放射線科

主な研究
乳がんの画像診断（MRI、超音波、マンモグラフィー）
Publication list: https://www.ncbi.nlm.nih.gov/myncbi/1x7vkeOvcDFQd/bibliography/public/

[ Personal Information ]
Akane Ohashi, M.D., Ph.D.
Nationality: Japanese
Date of Birth: March 15, 1982
Degree:
25 Apr. 2008 Physician’s License
23 Sep. 2020 Doctor of Philosophy, Medical Science, Department of Medicine Doctoral
Degree at the Graduate School of Medicine, Kyoto University, Masako Kataoka
(supervisor)
Research interest score 172.4, h-index: 13, citations: 422
(according to 2025-2-27 )
Original Articles 22 (4 first author)
Peer-Reviewed Conference Proceedings: 24

[ Education ]
Current position
10/2021- until now: Pos Doc., Department of Translational Medicine, Diagnostic Radiology, Lund University, Sweden
Previous position
11/2019-09/2021, 10/2023-03/2024: Pos Doc., Department of Diagnostic Imaging and Nuclear Medicine, Kyoto
University, Japan
04/2014-09/2019: Ph.D. student, Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University, Japan
04/2001-03/2007: Medical student, Tokyo Medical University, Japan

[ Work ]
Currently no employment
10/2023-03/2024 Radiologist, Medical Research Institute Kitano Hospital, Osaka
04/2020-09/2021 Radiologist, National Hospital Organization, Kyoto Medical Center, Kyoto
04/2014-03/2020 Radiologist, Kyoto University Hospital, Kyoto (18 months parental leave) 04/2012-03/2014 Radiology residency, Otsu City Hospital, Shiga,
04/2010-03/2011 Radiology residency, Osaka Red Cross Hospital, Osaka
04/2008-03/2009 Medical Intern, Nihon Medical University Hospital, Tokyo

[ Awards and Honors ]
The awarded scholarships
1) The 2024 Japan Society for the Promotion of Science (JSPS), Overseas Research Fellow
2) The 2023 Research grant of Bröst Cancer Förbundet
3) The 2023 Research grant of the Scandinavia-Japan Sasakawa Foundation
4) The 2022 international fellowship grant of the Japanese Scandinavian Radiological Society.
5) The 2021 Bayer Academic Encouragement Award and International Exchange Award of the Japanese Society for Magnetic Resonance in Medicine.
The awarded conference presentations
1) International Society for Magnetic Resonance in Medicine (ISMRM) diffusion Study Group, Awarded “Best Scientific Oral”, February 2, 2024, Web
2) Annual meeting of ISMRM, Educational Stipend, May 7-12, 2022, London
3) Annual meeting of ISMRM, Educational Stipend, May 15-20, 2021, Web
4) Annual meeting of ISMRM, Educational Stipend, Aug 8-14, 2020, Web
5) Workshop of ISMRM, Breast MRI: Advancing State of the Art, Educational Stipend, Sep 10-13, 2018, Las Vegas

[ CURRENT TITLE AND AFFILIATIONS ]
・Title: Professor

・Office: Department of Plastic & Reconstructive Surgery,
Yonsei University College of Medicine, Severance Hospital
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea

[ EDUCATION ]

[ ACADEMIC APPOINTMENTS ]

[ HONORS AND AWARDS ]

###

Professor Fiona Cheng, as the chairperson of the Taiwan Oncoplastic Breast Surgery Society (TOPBS) and a member of the Taiwan Surgery Association, has made significant contributions to the field of breast surgery in Taiwan.

Her expertise lies in breast oncoplastic and reconstructive surgery, as well as chemotherapy for breast cancer. Dr. Cheng's innovative work in recent years has focused on the development of a robotic-assisted nipple-sparing mastectomy and one-stage breast reconstruction techniques. These advancements have revolutionized the field of breast surgery, offering patients improved outcomes and minimizing the invasiveness of the procedures.

Since 2018, Dr. Cheng has successfully performed over 300 cases of robotic mastectomy and more than 500 cases of oncoplastic surgery. Her achievements have effectively realized the concept of minimally invasive breast surgery, ensuring patients receive the highest quality of care with reduced trauma and enhanced recovery.

Beyond her clinical expertise, Dr. Cheng is dedicated to the education and advancement of younger doctors in Taiwan. She actively participates in mentoring programs and workshops, sharing her knowledge and experience to foster the growth of breast surgery in the country. Her efforts have led to the establishment of Shin Wu Ho-Su Memorial Hospital as the first designated learning center for breast surgery in Taiwan, a testament to Dr. Cheng's pioneering work in robotic mastectomy.

Dr. Fiona Cheng's groundbreaking contributions, commitment to patient care, and passion for advancing the field of breast surgery have positioned her as a respected leader and mentor in the medical community in Taiwan.

NAME: Shin-Cheh Chen

ACADEMIC APPOINTMENT:

POST GRADUATE TRAINING:

PROFESSIONAL AFFILIATIONS:

PROFESSIONAL ACITIVITY:

RESEARCH INTEREST:

1. Surgical oncology.

2. Breast Surgical oncology.

Prof. Gabe Sonke, MD, PhD, is a distinguished medical oncologist and the Head of the Division of Medical Oncology at the Netherlands Cancer Institute in Amsterdam. He earned his MSc in Biomedical Health Sciences, PhD in Epidemiology, and MD from Radboud University in Nijmegen, Netherlands. Prof. Sonke completed his residencies in Internal Medicine at the University Medical Centre Utrecht and in Medical Oncology at the Netherlands Cancer Institute.

Prof. Sonke is a board member of the Dutch Medicines Evaluation Board and holds a professorship in Oncology at the University of Amsterdam. His research focuses on developing innovative treatments for breast and ovarian cancer, with a particular emphasis on reducing the adverse effects of cancer therapies. He has extensive experience in conducting and evaluating clinical drug research in oncology, significantly advancing cancer treatment and patient care. His work has been published in over 250 peer-reviewed journal articles.

Prof. Sonke is a member of several oncology societies, including the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research Project GENIE group, the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group, and the Dutch Gynaecological Oncology Group.

Key publications

1. Sonke GS, van Ommen-Nijhof A, Wortelboer N. et al. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer. Nature 2024 Nov 27
2. van der Voort A, Louis FM, van Ramshorst MS, […] Sonke GS. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol 2024;25: 603-613
3. van der Voort A, van Ramshorst MS, van Werkhoven ED, […] Sonke GS. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol 2021; 7: 978-984
4. van Driel WJ, Koole SN, Sikorska K, […], Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018; 378: 230-240

Education

License

Editor in Scientific Paper

Representative Bibliography

Original Articles within 3 years

1. Kook Y, Lee YJ, Chu C, Jang JS, Baek SH, Bae SJ, Cha YJ, Gong G, Jeong J, Lee SB, Ahn SG. Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis. Breast Cancer Res. 2024 Nov 6;26(1):154.
2. Bae SJ, Chun JW, Lee SB, Ryu JM, Nam SJ, Jeong J, Park HS, Ahn SG. Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study. Breast Cancer Res. 2024 Apr 17;26(1):66.
3. Lee M, Yoo TK, Chae BJ, Lee A, Cha YJ, Lee J, Ahn SG*, Kang J. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification. Sci Rep. 2024 May 17;14(1):11278.
4. Ahn SJ, Joo B, Park M, Park HH, Suh SH, Ahn SG*, Yoo J. Dural Metastasis in Breast Cancer: MRI-Based Morphological Subtypes and Their Clinical ImplicationsCancer Res Treat. 2024 Mar 19. doi: 10.4143/crt.2024.138. Online ahead of print.
5. Lee CM, Hwang Y, Jeong JW, Kim M, Lee J, Bae SJ, Ahn SG*, Fang S. BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer. Cell Death Discov. 2024 Jan 5;10(1):5.
6. Ji JH, Ahn SG*, Yoo Y, Park SY, Kim JH, Jeong JY, Park S, Lee I. Prediction of a Multi-Gene Assay (Oncotype DX and Mammaprint) Recurrence Risk Group Using Machine Learning in Estrogen Receptor-Positive, HER2-Negative Breast Cancer-The BRAIN Study. Cancers (Basel). 2024 Feb 13;16(4):774
7. Lee J, Lee YJ, Bae SJ, Baek SH, Kook Y, Cha YJ, Lee JW, Son BH, Ahn SH, Lee HJ, Gong G, Jeong J, Lee SB, Ahn SG*. Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer. JAMA Netw Open. 2023 Aug 1;6(8):e2330961.
8. Yoon CI, Hwang J, Kim D, Ji JH, Lee J, Bae SJ, Jeong J, Chang JS, Cho Y, Lee HS, Kim JY, Ahn SG*. Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery. Sci Rep. 2023 Sep 1;13(1):14372. doi: 10.1038/s41598-023-41301-3.
9. Bae SJ, Ahn SG*, Park EJ, Eun NL, Kim JH, Ji JH, Kook Y, Jang JS, Baek SH, Cha YJ, Jeong J. Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy. Radiology. 2023 Apr;307(2):e221777.
10. Lee J, Kim H, Bae SJ, Ji JH, Lee JW, Son BH, Ahn SH, Jeong J, Lee SB, Ahn SG. Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Netw Open. 2022 Nov 1;5(11):e2243935.
11. Ji JH, Bae SJ, Kim K, Chu C, Lee KA, Kim Y, Kim JH, Jeong J, Ahn SG. Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer. NPJ Breast Cancer. 2022 Feb 16;8(1):19. doi: 10.1038/s41523-022-00384-3.
12. Ahn SG, Bae SJ, Kim Y, Ji JH, Chu C, Kim D, Lee J, Cha YJ, Lee KA, Jeong J. Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR. NPJ Breast Cancer. 2022 May 2;8(1):58. doi: 10.1038/s41523-022-00424-y.
13. Ji JH, Bae SJ, Kim SG, Kim MH, Kim GM, Sohn J, Jeong J, Kim JH, Ahn SG. Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP. Cancer Med. 2022 Jul 15. doi: 10.1002/cam4.5022. Online ahead of print.
14. Baek SH, Kim JH, Bae SJ, Ji JH, Lee Y, Jeong J, Cha YJ, Ahn SG. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. Cancers (Basel). 2022 Jun 21;14(13):3042. doi: 10.3390/cancers14133042.
15. Ahn SG, Kim SK, Shepherd JH, Cha YJ, Bae SJ, Kim C, Jeong J, Perou CM. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Mar 26. doi: 10.1007/s10549-021-06193-9.
16. Cha C, Ahn SG*, Kim D, Lee J, Park S, Bae SJ, Kim JY, Park HS, Park S, Kim SI, Park BW, Jeong J. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Int J Cancer. 2021 Oct 15;149(8):1585-1592. doi: 10.1002/ijc.33726.

Review Articles

1. Ahn SG, Kim SJ, Kim C, Jeong J. Molecular Classification of Triple-Negative Breast Cancer. J Breast Cancer. 2016 Sep;19(3):223-230.
2. Ahn SG, Jeong J, Hong S, et al. Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med. 2015;49(5):355-63.
3. Park E, Ahn SG. Toripalimab: a new torchlight illuminating the path for metastatic triple negative breast cancer? 2024 Jul 22;5:23.

* It indicates co-first author or corresponding author

Shipra Gandhi, MD, MS Director, Breast Research
Co-Leader Breast Clinical Disease Site Team
Roswell Park Comprehensive Cancer Center

[ Personal Statement ]
I am a breast medical oncologist and a clinical investigator leading an active research program at Roswell Park, which spans the areas of clinical trials, biomarkers and translational research focusing on use of novel immunotherapy agents and role of psychosocial stress in triple negative breast cancer. Since my faculty appointment at Roswell Park in 2018, I have led several clinical trials, including 5 investigator initiated clinical trials. To date, I have published more than 60 peer-reviewed papers, many of which as first- or senior-author in high-impact and prestigious journals in my field. My research work has been well recognized and resulted in several national/international presentations. I have also received 6 grants as a PI, including 3 NIH grants. As a physician-scientist, my goal is to conduct innovative clinical trials using novel immunotherapy agents and take discoveries from the lab to the bedside to improve life expectancy as well as quality-of-life of cancer patients. As an educator, I strive to improve the quality of oncology education and mentor the next generation of clinician investigators.

Academic appointment(s)

[ Education ]

Profile

Chiun-Sheng Huang is the Professor of Surgery at the National Taiwan University Hospital and National Taiwan University College of Medicine and had been the Chairman of Department of Surgery from February, 2017 to July 31st, 2023. He is now the director of Breast Care Center at the National Taiwan University Hospital. He is Ex-President of Taiwan Breast Cancer Society and the chairman of Taiwan Breast Cancer Consortium (TBCC), an academic research organization focusing on multicenter clinical trials.

Prof. Huang has dedicated his career to the prevention and treatment of breast cancer. His research fields include ultrasound in breast cancer screening and axillary staging; computer-aided diagnosis of breast ultrasound; single nucleotide polymorphism and circulating tumor DNA as susceptibility and prognostic factor for breast cancer; and development of new regimens and biomarkers using neoadjuvant therapy. He has been the study chair of a nationwide randomized trial of breast cancer screening using ultrasound and mammography for women aged 40–49, and a multi-national randomized trial of active immunotherapy in metastatic breast cancer. He has also sit in the steering committees in 14 global trials investigating anti-Her-2 target therapies (LUX Breast-1, Kristine, Katherine, EirGenix EGC002, AptNeo, Destiny Breast05), anti-PDL1 antibody (NeoTrip) and CDK4/6 inhibitor (monarchE, NATALEE) for breast cancer in adjuvant and neoadjuvant setting and published 31 papers as co-authors in well-known journals, including N Engl J Med, Lancet Oncology, Journal of Clinical Oncology. Up to now, Prof. Huang has published more than 260 papers in breast cancer fields. He has been a panel member of the St. Gallen International Breast Cancer Consensus Expert Panel since 2017.

MEDICAL EDUCATION

School of Medicine
Kaohsiung Medical University Sep. 1984 ~ Jul.1991

Internship
Kaohsiung Medical University Hospital May 1990 ~ May 1991

Graduate School of Medicine
Kaohsiung Medical University Jul. 2003 ~ Jul. 2012
Kaohsiung, Taiwan

RESIDENCIES

Surgery Residency
Department of Surgery
Kaohsiung Medical University Hospital Aug. 1991 ~ Jul. 1996

ACADEMIC SERVICE

Professor
Department of Surgery, School of Medicine
Kaohsiung Medical University Feb. 2021~

Associate Professor
School of Medicine
Kaohsiung Medical University 2013 ~Jan. 2021

Director
Division of Molecular and Genetic Diagnosis
MedicoGenomic Research Center
Kaohsiung Medical University 2005 ~ Jul. 2006

Director
Taiwan Oncoplastic Breast Surgery Society Apr 2025-2028
Taiwan Breast Cancer Society May 2022 ~ May 2025
Taiwan Oncology Society Jun. 2022 ~ Jun. 2023

Deputy Secretary General
Taiwan Surgical Association May 2022 ~ May 2024

Secretary General
Taiwan Breast Cancer Society May 2019 ~ May 2022

Supervisor
Taiwan Breast Cancer Society May 2010 ~ May 2019

Sung-Bae Kim is a professor at Asan Medical Center, University of Ulsan, Seoul, Korea.

He attained MD and Ph D from Kyunghee Univerisity Medical School, completed clinical training in internal medicine at Ewha Womans University, and undertook a clinical fellowship at the Division of Hematology-Oncology at Asan Medical Center. He studied at the Experimental Transplantation and Immunology, National Cancer Institute, USA in 2000 as a postdoctoral fellow. He is a member of steering committees in international clinical trials. His research interests include tumor immunotherapy, molecular imaging, early drug development, and clinical management of head and neck, esophageal, and breast cancer. He has authored several book chapters and written over 400 articles in oncology peer-reviewed journals. He has been the principal investigator on a number of clinical trials. He is an author or co-author of high-impact journals. He had served as Head, Breast Cancer Center, Asan Medical Center, Mar 2018- Feb 2024, and as scientific co-chair, of ESMO Breast 2021-2023. He was one of the high-citation researchers in 2023 & 2024 by Clarivate.

ACADEMIC APPOINTMENTS

EDUCATION

RESIDENCY AND FELLOWSHIP

CURRENT POSITIONS

Education:

Employment Records:

Current Employment:

CURRENT POSITIONS

LICENSURE and CERTIFICATION:

EDUCATION

Current Appointments

* Professor of Department of Family Medicine, National Taiwan University (2022~)

* Director of Department of Family Medicine, National Taiwan University Hospital (2021~)

* Adjunct professor at College of Public Health, National Taiwan University (2021~)

* Director of Preventive Medicine, National Taiwan University Hospital (2016~)

* Editor, Annals of Family Medicine (2025~)

* Editor-in-Chief, Taiwan Journal of Hospice Palliative Care (2020~)

* President, Taiwan Academy of Hospice Palliative Medicine (2022~)

* Council member, Asia Pacific Hospice palliative care Network (APHN) (2024~)

Education

・College of Medicine, National Taiwan University, MD (1985-1992)

・Institute of Preventive Medicine, National Taiwan University, MSc (2002-2004)

・Bloomberg School of Public Health, Johns Hopkins University, DrPH (2006~2011)

Clinical training

Family Medicine, National Taiwan University Hospital

Clinical specialties

Preventive medicine: cancer screening, palliative medicine; family medicine

Professional Memberships：

・Chair of WONCA, Taiwan Association of Family Medicine

・President, Taiwan Academy of Hospice Palliative Medicine

・Director, Taiwan Association of International Health and Comprehensive Care

・Director, Taiwan Association of Comprehensive Care for Chronic Disease

・Member of European Association of Palliative Care

・Member of Asia Pacific Hospice palliative care Network

Honors and Awards：

* Distinguished publications and teaching materials, National Taiwan University Hospital, 2024

* Best oral presentation award, 1st place, Taiwan Association of Family Medicine, 2022

*Award for outstanding contribution (academic), Taiwan Academy of Hospice Palliative Medicine, 2019

* Fellowship, Taiwan College of Family Physicians, 2014

* Merck research award, Taiwan Association of Family Medicine, 2013

* Young scholar award, College of Medicine, National Taiwan University, 2012

* Young researcher award, Taiwan Association of Family Medicine, 2013

Kei Ouchi, MD, MPH is a clinician-scientist and clinically active as an associate physician in the emergency department (ED) and a home hospital physician in the Department of Medicine at Brigham and Women’s Hospital. Dr. Ouchi is an Associate Professor of Emergency Medicine at Harvard Medical School. After growing up in Osaka, Japan, Dr. Ouchi received his MD from Georgetown (2009), completed a Combined Emergency medicine/Internal Medicine Residency at Long Island Jewish Medical Center (2014), Health Policy Research Fellowship at Brigham and Women’s Hospital concurrently earning an MPH from Harvard (2016), and Psychosocial Oncology and Palliative Care Research Fellowship at Dana-Farber Cancer Institute (2018). Dr. Ouchi’s research focuses on identifying older adults who would benefit from advance care planning conversations and empowering them to formulate their goals for medical care in the ED. Dr. Ouchi teaches evidence-based, palliative care communication training locally, nationally, and internationally. Dr. Ouchi has published more than 90 peer-reviewed papers, some of which are featured in New York Times and Time Magazine. He is also a recipient of numerous awards, including the Paul B. Beeson Emerging Leaders Career Development Award in Aging from the National Institute on Aging, the Sojourns Scholars Leadership Award from the Cambia Health Foundation, and the Fulbright U.S. Scholar Award from the U.S. Department of State.

大阪生まれ。ジョージタウン大学医学部卒業。ニューヨークで内科・救急科合同研修を修了、米国内科専門医資格と米国救急専門医資格を取得。その後ボストン・ブリガムアンドウイマンズ病院にて医療政策研究フェローシップ、緩和医療研究フェローシップを終えてハーバード大学公衆衛生修士取得。現職ではブリガムアンドウイマンズ病院で救急診療とインターネットのビデオ通話を用いたホームホスピタル遠隔診療 （患者の自宅で病棟レベルの医療を提供）を指導医として提供している。医学論文90本以上執筆、ニューヨークタイムズ紙やタイム紙に掲載、ポールB・ビーソン老化研究キャリア開発新興リーダー賞(アメリカ国立衛生研究所)などを受賞、日本語の共書に救急医学・集中治療分野のアマゾン日本ベストセラー「緊急 ACP VitalTalk に学ぶ悪い知らせの伝え方,大切なことの決め方（医学書院）」や「アメリカでお医者さんにかかる時の本 (保健同人社)」などがある。

Prof. Dr. Sibylle Loibl is Chair of the German Breast Group and the Chief Executive Officer of the GBG Forschungs GmbH; Neu-Isenburg/Frankfurt/M, Germany

Prof. Dr. Loibl is a professor of obstetrics and gynecology at the Goethe University of Frankfurt. She gained a doctorate at the Ruprecht Karl University of Heidelberg and trained as a consultant in gynaecology and obstetrics. She devotes most of her time to clinical research within the German Breast Group.

Prof. Loibl has gained international renommée for her research in neoadjuvant breast cancer, breast cancer during pregnancy and young women. In addition, Prof. Loibl has been involved in conducting and managing a significant number of national and international, practice changing clinical trials.

Prof. Loibl is author of more than 500 original and peer review articles and scientific papers. She is an active member of many important national and international organizations, such as ASCO, ESMO, DKG and the AGO. She is involved in national and international guidelines for breast cancer, amongst them those for ESMO and ASCO. She led the ESMO guidelines for Early Breast Cancer 20024. She was Co-Founder of the ESMO Breast Conference and is an active faculty member of many international (ESMO, SABCS, SGBCC) conferences.

Professor Sabine Linn is a medical oncologist who is commi6ed to offer each cancer pa9ent op9mal care. She is the Medical Director of the Cell Therapy Program at the Netherlands Cancer Ins9tute and Group Leader in the Division of Molecular Pathology. Together with the Linn lab team members, she is dedicated to developing diagnos9c tests to define the best treatment for each breast cancer pa9ent preferring simple solu9ons to minimize harm to the planet and people. Furthermore, she is Professor of Transla9onal Oncology with focus on breast cancer at he University of Utrecht, the Netherlands.

Linn earned her MD from Leiden University in The Netherlands. She received a PhD in medicine about mul9drug resistance from the Free University in Amsterdam. She trained in internal medicine at the University Medical Center Utrecht before her oncology fellowship at the Netherlands Cancer Ins9tute. She also completed a postdoctoral research fellowship in molecular pathology at Stanford University. Professor Linn is an interna9onally renowned breast cancer expert, who has led and par9cipated in mul9ple clinical trials, and contributed to the development of diagnos9c tests for breast and ovarian cancer that are now used in daily clinical prac9ce.

POSITIONS HELD:

EDUCATION AND DEGREES:

・International Breast Cancer Center (IBCC), Barcelona, Spain

・Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain

・Medica Scentia Innovation Research (MedSIR), Barcelona, Spain & New Jersey, US

Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996, specialist in Medical Oncology by the Clínica Universitaria de Navarra, and awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. From June 2003 to July 2015, he has worked in the Department of Medical Oncology at the Hospital Vall d'Hebron, Barcelona, where he has been Coordinator of the Teaching and Training Programme for Residents in Oncology. In addition he was the Head of the Breast Cancer Program from July 2006 to August 2015. From September 2015 to October 2018, he has been Head of the Breast Cancer and Gynecological tumors at Ramon y Cajal University Hospital in Madrid. Dr. Cortes was the Head of the Breast Cancer Program at IOB Institute of Oncology, Quironsalud group, in both Madrid and Barcelona, from 2011 to September 2020. He has been Senior Clinical Investigator of the Breast Cancer Research Program at Vall d’Hebron Institute of Oncology from 2011 to February 2022.

Dr. Cortés is the Head of the International Breast Cancer Centre (IBCC) in Barcelona, founding partner of Medica Scientia innovation Research (MedSIR), a company involved in the clinical development of clinical trials.

In addition to his medical specialties, he has two master degrees in “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.

He has contributed to over 430 peer-reviewed publications, especially about breast tumours and new drugs and more than 800 communications at different conferences. He actively participates in the development of numerous international clinical trials, and he is an ad hoc reviewer of various oncology journals, including, New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology or Journal of Clinical Oncology, among many others

Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society for Medical Oncology (ESMO), of the Scientific Committee of the European Breast Cancer Conference (EBCC), has been chair for breast cancer at the ESMO 2020 congress, and co-chair of the same section in the congress of the American Association for Cancer Research (AACR) 2020, as well as the immunotherapy area of the AACR 2021 congress. He is a member of the expert panel that develops the treatment guidelines for metastatic breast cancer of the European Society for Medical Oncology, member of the ABC Conference, member of the ASCO International Affairs Committee, member of the executive panel in charge of SABCS Strategic Planning, and co-organizer of the Annual Congress of Controversies in Breast Cancer (CoBrCa).

In addition, according to the American Expertscape 2023 ranking, he is considered the world’s leading expert on HER2+ and fourth world oncologist with the greatest expertise in breast cancer and in 2022 and 2023 was identified as Clarivate™ world’s most influential researchers.

Director & Professor of Medicine
University of Hawaiʻi Cancer Center

Dr. Naoto Ueno joined the University of Hawai‘i Cancer Center in December 2022 and is now its director. Prior to this role, he was the Executive Director of the University of Texas MD Anderson Cancer Center's Inflammatory Breast Cancer (IBC) Research Program and Clinic and the Chief of the Section of Translational Breast Cancer Research in the Department of Breast Medical Oncology.

Dr. Ueno is renowned for developing a comprehensive research program and clinic focused on aggressive breast cancer, IBC, which has become the world's largest and most distinguished center for this rare form of breast cancer. His leadership and visionary approach have facilitated numerous collaborations on both local and global levels. Dr. Ueno fosters a team culture that values diversity, psychological safety, and research-driven compassionate patient care.

As a director, Dr. Ueno envisions building a world-class cancer center that excels in groundbreaking research and serves as a beacon of hope and innovation for the community. He is committed to integrating cutting-edge science with compassionate care, ensuring that advancements in research directly translate to improved patient outcomes. His vision includes expanding the center's reach and impact, particularly in underserved populations, and cultivating the next generation of cancer research and treatment leaders.

His research primarily explores the roles of various signaling pathways in triple-negative breast cancer (TNBC) and IBC, focusing on the tumor microenvironment and targeted therapies. Dr. Ueno has secured significant extramural funding, including NIH grants and awards from organizations such as CPRIT, DOD, and BCRF.

In addition to his research, Dr. Ueno leads several investigator-initiated clinical trials for advanced breast cancer and supports colleagues in obtaining research grants. He is also an experienced educator, teaching leadership, communication, and clinical research skills for drug development. He is a DDI-certified leadership facilitator, TEDx speaker, and author of two books on patient empowerment in cancer care.

As a two-time cancer survivor, Dr. Ueno brings a unique, comprehensive perspective to healthcare and passionately advocates for patient-centered, research-driven clinical care.

Education

[ EDUCATION ]

Academic Degree(s) (Bachelor’s and higher)

[ POSTDOCTORAL TRAINING ] (Include residency/fellowships)

Dr. Han received his MD and PhD degrees from the Seoul National University (SNU) College of Medicine, Korea. He has started faculty appointment in SNU since 2004. Starting from 2015, he has become a tenured Professor of SNU College of Medicine. He is former Chief of Breast Care Center in Seoul National University Hospital. He is now the Chairman of board of directors in Korean Breast Cancer Society (2023-2025) and Global Breast Cancer Conference (GBCC). He is also a member of board of directors in The Korean Cancer Association and Korea Genome Organization. He has been devoted to both breast cancer patient care and research. He has published more than 400 original articles in peer reviewed journals. His research interest includes breast cancer genomics, surgical techniques and their oncologic outcomes, and personalized treatment of breast cancer with new biomarkers. He is leading various ongoing multicenter trials in South Korea, such as PLATO and NAUTILUS.

CAREER HISTORY:

I have been Professor of Surgery for over 24 years and specialising in breast cancer, both clinical and research for over almost 40 years. My current interests include:-

1) Drug development and clinical trials in hormone sensitive breast cancer
I have been Chief investigator of a large number of Phase 2 and Phase 3 studies investigating multiple new drug treatments for patients with hormone sensitive breast cancer, many of these studies have been multicentre national or international randomised controlled trials. I also have been chief investigator on a number of pre-surgical randomised trials looking at pharmaco-dynamic and pharmacokinetic aspects of new drugs. I am a member of the Steering Committee of the Early Breast Cancer Clinical Triallist Group. I have also researched on factors associated with hormone sensitivity and resistance (de-novo and acquired).

2) Blood test for detection of early stage cancer
I developed a programme for the detection of early-stage cancer using a blood test I focused on the measurement of a panel of autoantibodies to cancer antigens rather than cancer antigens themselves as B-cell immune response provides an amplification of the early cancer signal. I developed the first blood test for the early detection of (lung) cancer measuring a panel of seven autoantibodies in the test called EarlyCDT-Lung (also called Nodify CDT Lung). A randomised controlled trial (ECLS) performed under the NHS in Scotland involved randomised over 12,000 smokers and ex-smokers and reported that patients randomised to the EarlyCDT-Lung test had a 36% reduction in diagnosis of late-stage lung cancers.

3) Breast Conserving Surgery for DCIS
I lead on a project looking at surgical margin width in breast conserving surgery (BCS) for ductal carcinoma in situ (DCIS) in the NHS Breast Screening Programme (BSP) auditing the results of actual surgical margin width against clinical outcomes (ie local recurrence and also overall survival). This is the first consecutive series from a national mammographic screening programme which report a continuing annual recurrence hazard rate out to 14 years without plateau, a high percentage of invasive recurrences (78%) as well as the significance in terms of recurrence risk of multiple surgeries to obtain clear margins.

4) Community Breast Pain Clinics for Patients with ‘Breast Pain only’
I also lead a programme which has developed and helped implement a new community-based pathway for patients with breast pain only. ~130,000 patients per annum in the UK with ‘breast pain alone’ have routinely been referred to urgent cancer diagnostic clinics when the breast pain per se does not carry any increased risk of being diagnosed with breast cancer: this raises significant anxiety, medicalises patients and at the same time can delay access of patients who do have ‘red flag’ cancer symptoms to the cancer diagnostic clinic. We have completed a 4-year programme of local, regional and national evaluation, the latter involving nine regional Cancer Alliances in England - with reproducible outcomes and excellent Patient Reported Outcome Measures (PROMs). The next step is to have the East Midlands Breast Pain Pathway adopted even more widely within the NHS.

Education

Current Position

Experience

Honors / Awards